HRP20100516T1 - Tiazolpirazolopirimidini kao antagonisti receptora crf1 - Google Patents

Tiazolpirazolopirimidini kao antagonisti receptora crf1 Download PDF

Info

Publication number: HRP20100516T1
Authority: HR; Croatia
Prior art keywords: pharmaceutically acceptable; acceptable salt; compound according; morpholin; methyl
Prior art date: 2006-09-20

Application number

HR20100516T

Other languages

English (en)

Croatian (hr)

Inventor

Chen Zhaogen

Hamdouchi Hamdouchi Chafiq

James Hembre Erik

Arthur Hipskind Philip

Kenneth Myers Jason

Takakuwa Takako

Lee Toth James

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2007-09-17

Publication date

2010-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-17 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2010-10-31 Publication of HRP20100516T1 publication Critical patent/HRP20100516T1/hr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HR20100516T 2006-09-20 2007-09-17 Tiazolpirazolopirimidini kao antagonisti receptora crf1 HRP20100516T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (fr)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1

Publications (1)

Publication Number	Publication Date
HRP20100516T1 true HRP20100516T1 (hr)	2010-10-31

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100516T HRP20100516T1 (hr)	2006-09-20	2007-09-17	Tiazolpirazolopirimidini kao antagonisti receptora crf1

Country Status (33)

Country	Link
US (1)	US8030304B2 (fr)
EP (1)	EP2094709B1 (fr)
JP (1)	JP5161226B2 (fr)
KR (1)	KR101088239B1 (fr)
CN (1)	CN101516887B (fr)
AR (1)	AR062886A1 (fr)
AT (1)	ATE481405T1 (fr)
AU (1)	AU2007297421B2 (fr)
BR (1)	BRPI0717023B8 (fr)
CA (1)	CA2663511C (fr)
CL (1)	CL2007002693A1 (fr)
CR (1)	CR10682A (fr)
CY (1)	CY1110854T1 (fr)
DE (1)	DE602007009305D1 (fr)
DK (1)	DK2094709T3 (fr)
EA (1)	EA015179B1 (fr)
ES (1)	ES2350282T3 (fr)
HR (1)	HRP20100516T1 (fr)
IL (1)	IL197614A (fr)
MA (1)	MA30798B1 (fr)
MX (1)	MX2009003125A (fr)
MY (1)	MY146388A (fr)
NO (1)	NO20091489L (fr)
NZ (1)	NZ575572A (fr)
PE (1)	PE20081377A1 (fr)
PL (1)	PL2094709T3 (fr)
PT (1)	PT2094709E (fr)
RS (1)	RS51545B (fr)
SI (1)	SI2094709T1 (fr)
TN (1)	TN2009000095A1 (fr)
TW (1)	TWI402269B (fr)
UA (1)	UA96458C2 (fr)
WO (1)	WO2008036579A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2350079B1 (fr) *	2008-10-02	2012-11-14	Eli Lilly & Company	Composés de thiazolylpyrazolopyrimidine à usage d'intermédiaires de synthèse et procédés de synthèse associés
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
CN106102740A (zh) *	2014-01-21	2016-11-09	纽罗克里生物科学有限公司	治疗先天性肾上腺增生的crf1受体拮抗剂
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
AU2017324942B2 (en)	2016-09-07	2022-01-27	The Regents Of The University Of California	Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-Tau and improve cognition
KR20200040761A (ko) *	2017-08-14	2020-04-20	스프루스 바이오사이언시스 인코포레이티드	코티코트로핀 방출 인자 수용체 길항제
WO2019036472A1 (fr) *	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	Antagonistes du récepteur du facteur de libération de la corticotropine
JP7427655B2 (ja) *	2018-04-27	2024-02-05	スプルースバイオサイエンシーズ，インク．	精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
JP7238130B2 (ja)	2018-12-07	2023-03-13	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
AU2020318970A1 (en) *	2019-07-19	2022-03-03	Spruce Biosciences, Inc.	Methods of treating congenital adrenal hyperplasia
JP7623365B2 (ja)	2019-09-27	2025-01-28	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
AR120649A1 (es) *	2019-12-04	2022-03-09	Neurocrine Biosciences Inc	Antagonistas del receptor de crf y métodos de uso
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
AU2021324839B2 (en)	2020-08-12	2024-02-29	Spruce Biosciences, Inc.	Methods and compositions for treating polycystic ovary syndrome
EP4203964A1 (fr)	2020-08-26	2023-07-05	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf et méthodes d'utilisation
AU2022240609A1 (en)	2021-03-19	2023-09-28	Crinetics Pharmaceuticals, Inc.	Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
WO2023091684A1 (fr) *	2021-11-19	2023-05-25	Spruce Biosciences, Inc.	Composition cristalline de tildacerfont et ses méthodes d'utilisation et de préparation
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (fr) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques
WO2025188842A1 (fr) *	2024-03-08	2025-09-12	Spruce Biosciences, Inc.	Dispersion solide amorphe de formulations de tildacerfont

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0674641B1 (fr)	1992-12-17	1999-03-03	Pfizer Inc.	Pyrrolopyrimidines en tant qu'antagonistes du facteur liberateur de corticotrophine (crf)
BR9707391A (pt) *	1996-02-07	1999-07-20	Janssen Pharmaceutica Nv	Pirazolpirimidinas como antagonistas de receptor de crf
NZ333777A (en) *	1996-07-24	2000-07-28	Du Pont Pharm Co	(1,5-a) pyrazolo and triazole triazines and pyrimidines
CZ2005613A3 (cs)	1996-07-24	2017-01-25	Bristol-Myers Squibb Pharma Company	Azolopyrimidiny, jejich použití a farmaceutické kompozice na jejich bázi
DE69736711T2 (de)	1996-08-28	2007-09-20	Pfizer Inc.	Substituierte 6,5-heterobicyclische-derivate
EP1040831A3 (fr) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4203500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
EP1218381B1 (fr) *	1999-09-30	2006-12-06	Neurogen Corporation	PYRAZOLO¬1,5-a\|-1,5-PYRIMIDINES ET PYRAZOLO¬1,5-a\|-1,3,5-TRIAZINES AMINO SUBSTITUEES
CA2440553C (fr)	2001-03-13	2010-06-08	Paul J. Gilligan	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, ses enantiomeres et sels pharmaceutiquement acceptables en tant que ligands du recepteur de la corticoliberine
TW200530242A (en)	2003-12-22	2005-09-16	Sb Pharmco Inc	CRF receptor antagonists and methods relating thereto

2007
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 EP EP07842582A patent/EP2094709B1/fr active Active
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 CA CA2663511A patent/CA2663511C/fr active Active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/fr active Application Filing
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
NZ575572A (en)	2011-10-28
BRPI0717023B1 (pt)	2019-11-19
UA96458C2 (ru)	2011-11-10
CR10682A (es)	2009-08-13
CN101516887B (zh)	2011-11-02
JP2010504344A (ja)	2010-02-12
NO20091489L (no)	2009-04-16
US8030304B2 (en)	2011-10-04
US20100222339A1 (en)	2010-09-02
SI2094709T1 (sl)	2011-01-31
CL2007002693A1 (es)	2008-04-18
EA015179B1 (ru)	2011-06-30
HK1132505A1 (en)	2010-02-26
TW200821312A (en)	2008-05-16
TWI402269B (zh)	2013-07-21
MY146388A (en)	2012-08-15
CA2663511C (fr)	2012-12-04
CN101516887A (zh)	2009-08-26
AR062886A1 (es)	2008-12-10
KR101088239B1 (ko)	2011-11-30
CA2663511A1 (fr)	2008-03-27
JP5161226B2 (ja)	2013-03-13
AU2007297421B2 (en)	2012-03-08
BRPI0717023B8 (pt)	2021-05-25
ATE481405T1 (de)	2010-10-15
DE602007009305D1 (de)	2010-10-28
AU2007297421A1 (en)	2008-03-27
CY1110854T1 (el)	2015-06-10
BRPI0717023A2 (pt)	2014-03-11
IL197614A (en)	2012-10-31
DK2094709T3 (da)	2010-12-06
WO2008036579A1 (fr)	2008-03-27
TN2009000095A1 (en)	2010-08-19
PT2094709E (pt)	2010-10-04
EA200970303A1 (ru)	2009-10-30
RS51545B (en)	2011-06-30
MX2009003125A (es)	2009-05-28
MA30798B1 (fr)	2009-10-01
KR20090052366A (ko)	2009-05-25
PL2094709T3 (pl)	2011-02-28
ES2350282T3 (es)	2011-01-20
EP2094709B1 (fr)	2010-09-15
PE20081377A1 (es)	2008-09-18
IL197614A0 (en)	2009-12-24
EP2094709A1 (fr)	2009-09-02

Publication	Publication Date	Title
HRP20100516T1 (hr)	2010-10-31	Tiazolpirazolopirimidini kao antagonisti receptora crf1
HRP20200624T1 (hr)	2020-07-10	Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka
CN101072779B (zh)	2010-12-22	2,4(4,6)嘧啶衍生物
JP5323095B2 (ja)	2013-10-23	ピロロ［２，３−ｄ］ピリミジンおよびそのチロシンキナーゼ阻害剤としての使用
JP2010504344A5 (fr)	2010-10-28
RU2015154676A (ru)	2017-07-28	Соединения для лечения спинальной мышечной атрофии
JP5091944B2 (ja)	2012-12-05	イミダゾ［１，２−ｂ］ピリダジン、その調製方法及びＧＡＢＡ受容体リガンドとしてのその使用
HRP20180746T4 (hr)	2020-02-21	Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
NZ598907A (en)	2014-03-28	Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
TW200730531A (en)	2007-08-16	7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amine
RU2009136299A (ru)	2011-04-10	Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
NZ600229A (en)	2014-06-27	Triazolopyridines
NZ590784A (en)	2012-12-21	Pyrazolopyridine kinase inhibitors
JP2007523151A5 (fr)	2008-02-28
IL210071A (en)	2016-02-29	Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
NZ600927A (en)	2013-08-30	N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors
TW200745130A (en)	2007-12-16	2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
HRP20120918T1 (hr)	2012-12-31	Aminopirazolski spoj
JP2013542963A5 (fr)	2015-01-08
PE20090944A1 (es)	2009-08-09	PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
RU2005136166A (ru)	2006-06-10	2-алкинил -и 2-алкенил-пиразол-[4, 3-е]-1. 2. 4-триазоло-[1. 5-с]-пиримидиновые антагонисты а рецептора аденозина
JP2007509158A5 (fr)	2007-07-26
JP2010509224A5 (fr)	2010-12-24
TW200942546A (en)	2009-10-16	A crystalline form of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one
FI3894411T3 (fi)	2024-08-15	7-fenoksi-n-(3-atsabisyklo[3.2.1]oktan-8-yyli)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triatsoli-2-amiinijohdannaisia ja niihin liittyviä yhdisteitä gammasekretaasin modulaattoreina alzheimerin taudin hoitoon